(Q88688834)

English

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

scientific article published on 12 June 2018

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

semaglutide

5 May 2024

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Stephen L. Atkin

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Lawrence A Leiter

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

author name string

Guillaume Charpentier

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Sune Birch

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

publication date

12 June 2018

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

2210-2219

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Obesity as a disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life in relation to overweight and body fat distribution.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Ph

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collab

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Parallel, redundant circuit organization for homeostatic control of feeding behavior

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

GLP-1 receptor agonists: a review of head-to-head clinical studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Parabrachial CGRP Neurons Control Meal Termination

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of Weight Loss Maintenance and Weight Regain on 4-Year Changes in CVD Risk Factors: the Action for Health in Diabetes (Look AHEAD) Clinical Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentr

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comment on American Diabetes Association. Standards of Medical Care in Diabetes-2017. Diabetes Care 2017;40(Suppl. 1):S1-S135

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/29766634

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/DOM.13353

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29766634%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q88688834&oldid=2145724278"